Stryker (NYSE:SYK) had its price target hoisted by equities research analysts at Citigroup from $227.00 to $232.00 in a report issued on Friday, The Fly reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. Citigroup‘s price objective would suggest a potential upside of 20.02% from the company’s previous close.
A number of other equities analysts have also recently commented on the stock. Morgan Stanley lifted their target price on shares of Stryker from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Friday, May 1st. Cfra lowered their price objective on shares of Stryker from $234.00 to $231.00 and set a “strong-buy” rating on the stock in a research report on Friday, May 1st. Raymond James lowered their price objective on shares of Stryker from $240.00 to $205.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Deutsche Bank lowered their price objective on shares of Stryker from $243.00 to $228.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Barclays lowered shares of Stryker from an “equal weight” rating to an “underweight” rating and set a $155.00 target price on the stock. in a research report on Monday, April 13th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $216.25.
SYK stock opened at $193.30 on Friday. The company has a current ratio of 2.58, a quick ratio of 1.77 and a debt-to-equity ratio of 0.72. Stryker has a twelve month low of $124.54 and a twelve month high of $226.30. The company’s 50 day moving average is $186.61 and its two-hundred day moving average is $189.31. The stock has a market cap of $72.45 billion, a P/E ratio of 28.10, a PEG ratio of 3.36 and a beta of 0.84.
Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. The business had revenue of $2.76 billion for the quarter, compared to analysts’ expectations of $2.63 billion. Stryker had a net margin of 11.38% and a return on equity of 20.53%. On average, equities research analysts predict that Stryker will post 6.26 earnings per share for the current year.
In other news, Director Srikant M. Datar sold 200 shares of Stryker stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $186.01, for a total transaction of $37,202.00. Following the sale, the director now owns 17,686 shares of the company’s stock, valued at approximately $3,289,772.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Srikant M. Datar sold 350 shares of Stryker stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $191.20, for a total value of $66,920.00. Following the sale, the director now directly owns 17,226 shares in the company, valued at approximately $3,293,611.20. The disclosure for this sale can be found here. Insiders have sold a total of 30,670 shares of company stock worth $5,775,251 in the last three months. 6.80% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of SYK. Sofos Investments Inc. lifted its position in shares of Stryker by 160.0% during the 1st quarter. Sofos Investments Inc. now owns 728 shares of the medical technology company’s stock worth $26,000 after buying an additional 448 shares during the period. Evolution Wealth Advisors LLC lifted its position in shares of Stryker by 64.4% during the 2nd quarter. Evolution Wealth Advisors LLC now owns 143 shares of the medical technology company’s stock worth $26,000 after buying an additional 56 shares during the period. WASHINGTON TRUST Co bought a new position in shares of Stryker during the 1st quarter worth approximately $28,000. Filbrandt Wealth Management LLC bought a new position in shares of Stryker during the 1st quarter worth approximately $30,000. Finally, Ballast Advisors LLC bought a new position in Stryker in the 1st quarter valued at $31,000. Institutional investors and hedge funds own 71.24% of the company’s stock.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More: What is a bull market?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.